UK markets close in 3 hours 20 minutes
  • FTSE 100

    7,161.19
    +101.74 (+1.44%)
     
  • FTSE 250

    22,849.24
    +329.52 (+1.46%)
     
  • AIM

    1,195.00
    +7.44 (+0.63%)
     
  • GBP/EUR

    1.1767
    +0.0041 (+0.35%)
     
  • GBP/USD

    1.3319
    +0.0018 (+0.13%)
     
  • BTC-GBP

    42,990.31
    -834.39 (-1.90%)
     
  • CMC Crypto 200

    1,469.49
    +26.72 (+1.85%)
     
  • S&P 500

    4,567.00
    -88.27 (-1.90%)
     
  • DOW

    34,483.72
    -652.22 (-1.86%)
     
  • CRUDE OIL

    68.88
    +2.70 (+4.08%)
     
  • GOLD FUTURES

    1,788.00
    +11.50 (+0.65%)
     
  • NIKKEI 225

    27,935.62
    +113.86 (+0.41%)
     
  • HANG SENG

    23,658.92
    +183.66 (+0.78%)
     
  • DAX

    15,387.17
    +287.04 (+1.90%)
     
  • CAC 40

    6,841.07
    +119.91 (+1.78%)
     

Olink announces participation in November investor events

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

UPPSALA, Sweden, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that it will be participating in two investor events in November.

Olink virtual investor day with proteomics KOLs
On November 15th, 2021, from 12:30pm to 3:30pm ET (6:30pm to 9:30pm CET), Olink will host a virtual investor day, providing direct access to key opinion leaders from leading universities and BioPharma companies, discussing exciting research projects where Olink is a proud contributor, while also providing an overview of Olink’s commercial plans.

Nordic Post IPO Seminar 2021
Oskar Hjelm, CFO, will participate in the Nordic Post IPO Seminar 2021, on November 24th, from 4:00am to 4:45am ET (10:00am to 10:45 am CET) hosted by Handelsbanken Capital Markets.

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Olink IR Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Olink Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: + 46 768 775 275
andrea.prander@olink.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting